The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Exploring the Efficacy of Pembrolizumab in Sarcoma Subtypes

Lisa H. Butterfield, PhD
Published Online:6:33 PM, Thu August 31, 2017

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, and president of the Society for Immunotherapy of Cancer, discusses the SARC028 study, which explored the efficacy of pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.